* For illustration purpose only
|25.0 mg (EU2EU)||30 pills||€136.00|
|25.0 mg (EU2EU)||60 pills||€158.00|
|25.0 mg (EU2EU)||90 pills||€183.00|
|25.0 mg (EU2EU)||120 pills||€208.00|
|25.0 mg (EU2EU)||180 pills||€236.00|
Strattera medication belongs to the group of psychomotor stimulants and nootropics. The effect of the drug is based on central sympathomimetic action. Selectively binding to transport proteins involved in the reuptake of the norepinephrine presynaptic gap, Strattera blocks its transfer. An increase in the concentration of the mediator norepinephrine in the presynapse causes an improvement in cognitive functions, stabilization of attention and spatial working memory. Through noradrenergic modulation of the work of the prefrontal areas of the cortex, Strattera enhances brake control, thereby eliminating excessive impulsivity.
Strattera is indicated in the treatment of ADHD in children after 6 years of age, in the complex treatment of adolescents and adults.
How to use this drug? Appointment of treatment is carried out by a specialist with experience in managing patients suffering from attention deficit disorder and disorders of motor activity. With the ineffectiveness of a single dose of the drug, it is necessary to divide the daily dose into two doses: in the morning and in the evening. Depending on the actual body weight of the patient, the doctor determines the daily amount of the drug.
Deterioration in appetite, dry mouth, discomfort and pain in the abdomen, constipation, and flatulence are the most common adverse Straterra side effects. Additional effects may include:
•Changes in the central nervous system are manifested by dizziness, sleep disturbances in the form of spontaneous awakening, sinus cranialgia, and libido disorders. •On the part of the vasomotor system, it can be a subjective feeling of a surge to the upper half of the body, face, heart palpitations, arrhythmias, cold extremities, or even peripheral reactions like Raynaud's syndrome.
•Allergic reactions when using the drug are manifested as angioedema, urticaria.
•The drug may have a hepatotoxic effect in the form of jaundice. With laboratory confirmation of hepatic dysfunction, Strattera should be discontinued. •During therapy with Strattera, suicidal thoughts may appear in patients. The use of Strattera in patients with severe organic cardiopathology can cause sudden cardiac death.
•Patients receiving Strattera for ADHD need to systematically monitor manifestations of aggression and hostility on the part of doctors. Psychotic reactions, manic and delusional syndromes, agitation, impulsivity, panic attacks, and akathisia require systematic monitoring of patients.
Withdrawal syndrome at the end of therapy was not detected.
Last updated: 4.06.2020